RecruitingPhase 2/3

Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis

China60 participantsStarted 2026-03-01

Plain-language summary

To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age and Gender: Patients aged 18 to 80 years (inclusive of boundary values), regardless of gender.
✓. Diagnosis and Treatment: Patients with head and neck cancer (including nasopharyngeal carcinoma) who have been confirmed by histopathology and require radical radiotherapy or postoperative adjuvant radiotherapy.
✓. Performance Status: Patients with an ECOG Performance Status score of 0 to 2.
✓. Consent: Patients who voluntarily agree to participate in this study and sign the informed consent form.

Exclusion criteria

✕. Prior Radiotherapy: Patients with a history of prior radiotherapy to the target area.
✕. Baseline Skin Condition: Baseline skin condition in the treatment area that may interfere with efficacy assessment (e.g., presence of open wounds, infection, rash, psoriasis, etc.).
✕. Systemic Diseases: Presence of connective tissue diseases or other systemic dermatoses.
✕. Known Allergies: Known allergy to any component of the investigational product (Meilian Fuxin Solution).
✕. Prior Clinical Research: Participation in other interventional clinical studies within the past 3 months and use of any investigational drugs or devices.
✕. Investigator Discretion: Subjects judged by the investigator to be unsuitable for participation in this clinical study.

What they're measuring

Incidence of Grade 2 or Higher Acute Radiation Dermatitis (RTOG Criteria)

Timeframe: The evaluation period is approximately 14 weeks to 14.5 weeks.

Trial details

NCT IDNCT07353671

SponsorWest China Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

Contact for this trial

Xingchen Peng

+86 18980606753 pxx2014@163.com

View on ClinicalTrials.gov More Radiation-induced Dermatitis trials